Jasper Therapeutics, Inc.JSPR
Price (close)
$0.59
Market cap
$16.4M
P/E
—
Revenue (TTM)
—
Net income
-$31.8M
Dividend yield
—
1-year total return
-74.9%
Net margin
—
Revenue growth
—
Debt / equity
—
What Jasper Therapeutics, Inc. does.
are a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous
in mast cell driven diseases for potential future development. We have also historically explored development programs in diseases where
targeting diseased hemopoietic stem cells can provide benefits, such as stem cell transplant conditioning regimens, but those programs
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$31.7M | -$30.6M | -$37.7M | -$64.5M | -$71.3M | -$75.8M |
More on JSPR.
- Jasper Therapeutics, Inc. summary
- Jasper Therapeutics, Inc. financial statements
- Jasper Therapeutics, Inc. key metrics
- Jasper Therapeutics, Inc. health scores and style box
- Jasper Therapeutics, Inc. earnings
- Jasper Therapeutics, Inc. dividends
- Jasper Therapeutics, Inc. valuation
- Jasper Therapeutics, Inc. ownership and insiders
- Jasper Therapeutics, Inc. peers
Figures from Jasper Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.